RESUMEN
Lobectomy has been the primary treatment modality for resectable non-small cell lung cancer.However, recent data showed that surgery alone is not adequate for resectable NSCLC treatment. All patients eligible for surgery with curative intent (stage Ⅰ,Ⅱ,and ⅢA) may benefit from adjuvant chemotherapy.Although combined chemoradiation may improve local control for stage ⅢA disease,radiotherapy has been shown to be harmful for patients with stage Ⅰ and Ⅱ NSCLC after complete resection.The role of neoadjuvant chemotherapy or chemoradiation in resectable NSCLC is controversial.RTOG and SWOG have initiated a phase Ⅲ randomised trial to evaluate the effect of preoperative combined chemoradiation followed by surgical resection and consolidation chemotherapy for stage ⅢA disease.In this review,we discuss the current status of combined management of NSCLC and forecast the future direction of treatment by reviewing a number of landmark publications and ongoing clinical trials..